# US 12,005,207 B2 · Chemical ablation and method of treatment for various diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,207 B2
- Document ID: US12005207B2
- Status: Granted
- Kind: B2
- Application number: 16/986,717
- Filed: 2020-08-06
- Published: 2020-11-19
- Granted: 2024-06-11
- Earliest claimed: 2014-10-30
- Assignees: Neurotronic, Inc.
- Applicants: Neurotronic, Inc.
- Inventors: Lixiao Wang; John J. Chen; Yongxing Zhang
- Web page: https://patentgrep.com/patent/US12005207B2

## CPC

- A61M 25/1002: {characterised by balloon shape (A61M25/1006, A61M25/1009 take precedence)}
- A61B 18/06: caused by chemical reaction {, e.g. moxaburners}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61M 5/007: {for contrast media}
- A61M 5/142: Pressure infusion, e.g. using pumps
- A61M 5/172: electrical or electronic
- A61M 25/1011: {Multiple balloon catheters}
- A61M 29/02: Dilators made of swellable material {(balloon catheters for angioplasty A61M25/104)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61B 2018/00577: {Ablation}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M 2025/1052: {for temporarily occluding a vessel for isolating a sector}
- A61M 2202/02: Gases
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

## Claims

### Claim 1

A method for treating diabetes and obesity, the method comprising:
inserting a first delivery catheter that is a needle catheter or a needle-based catheter into a first treatment site in a common hepatic artery;
infusing a chemical formulation from a formulation infusion lumen of the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the first treatment site;
withdrawing the first delivery catheter from the first treatment site;
inserting a second delivery catheter that is the same or different as the first delivery catheter and that is a needle catheter or a needle-based catheter into a second treatment site in the common hepatic artery, wherein the second treatment site is a different treatment site than the first treatment site;
infusing a chemical formulation from a formulation infusion lumen of the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the second treatment site; and
withdrawing the second delivery catheter from the second treatment site;
wherein the injury and/or damage to the tissue at the first treatment site and to the tissue at the second treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight; and
wherein the first and/or second delivery catheter comprises a balloon around a circumference of a shaft and the formulation infusion lumen in the shaft that passes through a region of the shaft that comprises the balloon thereon.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises:
inflating the balloon after the insertion to the first treatment site and deflating the balloon prior to the withdrawing from the first treatment site; and/or
inflating the balloon after the insertion to the second treatment site and deflating the balloon prior to the withdrawing from the second treatment site.

### Claim 3 (depends on 1)

The method of claim 1, wherein the chemical formulation comprises one or more ingredients chosen from water, saline, hypertonic saline, phenol, methanol, ethanol, absolute alcohol, isopropanol, propanol, butanol, isobutanol, ethylene glycol, glycerol, acetic acid, lactic acid, propyl iodide, isopropyl iodide, ethyl iodide, methyl acetate, ethyl acetate, ethyl nitrate, isopropyl acetate, ethyl lactate, lipiodol, urea, and derivatives thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the chemical formulation comprises ethanol, acetic acid, ethanol and water, an ethanol/water azeotrope, or ethanol and acetic acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein the chemical formulation comprises ethanol.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method comprises infusing heat from the first and/or second delivery catheter to the tissue of the body lumen at the first and/or second treatment site.

### Claim 7 (depends on 1)

The method of claim 1, further comprising:
inserting a third delivery catheter that is a needle catheter or a needle-based catheter into a third treatment site in a renal artery;
infusing a chemical formulation from a formulation infusion lumen of the third delivery catheter to a tissue of the body lumen at the third treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the third treatment site; and
withdrawing the third delivery catheter from the third treatment site.

### Claim 8

A method for treating diabetes and obesity, the method comprising:
inserting a first delivery catheter that is a needle catheter or a needle-based catheter into a first treatment site in a common hepatic artery;
infusing a chemical formulation from a formulation infusion lumen of the first delivery catheter to a tissue of the body lumen at the first treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the first treatment site;
withdrawing the first delivery catheter from the first treatment site;
inserting a second delivery catheter that is the same or different as the first delivery catheter and that is a needle catheter or a needle-based catheter into a second treatment site in the common hepatic artery, wherein the second treatment site is a different treatment site than the first treatment site;
infusing a chemical formulation from a formulation infusion lumen of the second delivery catheter to a tissue of the body lumen at the second treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the second treatment site;
withdrawing the second delivery catheter from the second treatment site;
inserting a third delivery catheter that is a needle catheter or a needle-based catheter into a third treatment site in a renal artery;
infusing a chemical formulation from a formulation infusion lumen of the third delivery catheter to a tissue of the body lumen at the third treatment site, wherein the chemical formulation infused is effective to injure and/or damage the tissue at the third treatment site; and
withdrawing the third delivery catheter from the third treatment site;
wherein the injury and/or damage to the tissue at the first treatment site, at the second treatment site, and at the third treatment site is effective to have a benefit of relieving symptoms comprising reduction of HbA1c (A1c), glucose level, and body weight.